Retinitis Pigmentosa Treatment Market Size & Overview
Retinitis Pigmentosa Treatment Market size reached US$ 5.72 Billion in 2024 and is expected to reach US$ 11.13 Billion by 2033, growing at a CAGR of 7.7% during the forecast period 2026-2033.
The retinitis pigmentosa treatment market is poised for robust expansion, underpinned by groundbreaking gene and cell therapies, growing diagnostic capabilities, and increasing patient engagement. Stakeholders ranging from large pharma to specialized biotech must navigate high development costs, regulatory complexities, and access barriers to capitalize on this high-growth opportunity. A strategic focus on personalized approaches, digital health integration, and emerging market access will be critical for sustainable leadership in this evolving therapeutic landscape.
Executive Summary
For more details on this report – Request for Sample
Retinitis Pigmentosa Treatment Market Dynamics: Drivers & Restraints
Rising demand for innovative therapeutics is significantly driving the retinitis pigmentosa treatment market growth
Retinitis Pigmentosa is a rare genetic disorder with very limited treatment options. The lack of effective therapies for the condition creates a substantial unmet medical need, expected to increase the demand for innovative solutions that can address the causes of the disease and provide meaningful benefits to patients. The major market players are performing clinical trials to develop innovative therapeutics.
Innovative therapeutics, such as gene therapies and advanced treatments, have the potential to offer improved patient outcomes compared to other traditional or symptomatic approaches. Patients and healthcare providers often seek treatments that can not only manage symptoms but also slow down or halt the progression of the disease. So, there is an increasing demand for innovative gene therapies. Thus, market players are focusing on developing gene therapies, boosting the market growth.
For instance, in February 2025, Ocugen, Inc., a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, announced that the European Commission has provided a positive opinion from the European Medicines Agency’s (EMA) Committee for Advanced Therapies (CAT) for OCU400 Advanced Therapy Medicinal Product (ATMP) classification. OCU400 is the first gene therapy to enter Phase 3 with a broad retinitis pigmentosa (RP) indication.
Additionally, in May 2025, Skyline Therapeutics, an innovation-driven clinical-stage gene therapy company focused on developing unique and novel solutions for rare and severe diseases, announced a late-breaking abstract presentation on SKG1108, its investigational optogenetic gene therapy for Retinitis Pigmentosa (RP), at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting.
Availability of limited approved treatment options is hampering the retinitis pigmentosa treatment market's growth
Luxturna (voretigene neparvovec), the only FDA-approved gene therapy for retinitis pigmentosa, is indicated solely for biallelic RPE65 mutations, present in fewer than 5% of all retinitis pigmentosa patients. This leaves the vast majority of retinitis pigmentosa sufferers without any approved gene-based option. With over 60 genes implicated in retinitis pigmentosa, each requiring separate clinical development and regulatory review, few companies have the resources to pursue more than a handful of indications. The time and expense of running dozens of small, mutation-specific trials create a de-risking challenge for investors.
The lack of multiple approved therapies reflects the technical and regulatory challenges in developing RP treatments, such as difficulties in designing clinical trials for rare mutations and proving long-term efficacy. Biotech firms and investors may hesitate to fund RP drug development due to uncertain regulatory pathways and limited precedent for approval, thereby slowing innovation.
The limited number of approved RP treatments, exemplified by Luxturna’s narrow mutation target and the absence of other widely accepted therapies, restricts market growth by limiting patient access, increasing development risk, complicating reimbursement, and dampening demand. Expanding approved treatment options across diverse RP genotypes is critical for unlocking the full market potential.
Retinitis Pigmentosa Treatment Market Segmentation Analysis
The global retinitis pigmentosa treatment market is segmented based on disease type, treatment type, and region.
The gene therapy from the treatment type segment is expected to hold 59.75% of the market share in 2025 in the retinitis pigmentosa treatment market
The gene therapy segment is expected to hold the largest market share over the forecast period. Gene therapy for retinitis pigmentosa involves introducing functional copies of a defective gene into the patient's cells to compensate for the genetic mutation causing the condition. Voretigene neparvovec-ryzl (Luxturna) is the only gene therapy product approved by the FDA to treat a specific type of retinitis pigmentosa with mutations in both copies of the RP65 gene. Luxturna delivers a functional copy of the RPE65 gene to the retinal cells, aiming to restore vision.
Besides Luxturna, various other gene therapies for retinitis pigmentosa are under investigation in clinical trials. These trials are exploring different gene therapy approaches, including the use of various viral vectors to deliver therapeutic genes, to address various genetic mutations associated with the condition. The major market players are focusing on the development of gene therapies for the management of retinitis pigmentosa, which is driving the segment’s growth.
For instance, in May 2025, Beacon Therapeutics Holdings Limited announced 6-month interim safety and efficacy results from the Phase 2 DAWN trial of the Company’s lead program, laru-zova (laruparetigene zovaparvovec), in patients with X-linked retinitis pigmentosa (XLRP). Laru-zova is a potential best-in-class gene therapy designed to restore the natural function of both rods and cones in XLRP by delivering a functional copy of the RPGRORF15 gene using a well-established vector with a proprietary capsid designed for high transduction of photoreceptors, and a codon-optimized gene to produce the full-length protein.
Additionally, in January 2025, ViGeneron GmbH, a next-generation clinical-stage gene therapy company, announced two important milestones for its novel gene therapy candidate VG901, to treat patients with retinitis pigmentosa (RP) caused by mutations in the CNGA1 gene. The U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) to VG901, and the independent Data Safety Monitoring Board (DSMB) has unanimously approved dose escalation in the ongoing Phase 1b clinical trial.
Retinitis Pigmentosa Treatment Market Geographical Analysis
North America is expected to dominate the global retinitis pigmentosa treatment market with a 46.98% share in 2025
North America region is expected to hold the largest market share over the forecast period, owing to the strong presence of major players and increasing research activities for developing advanced therapies. North America, especially the United States and Canada, is a known hub for its strong presence of major players such as pharmaceutical companies, which actively focus on the development of novel therapies for better treatment.
For instance, in August 2024, Ocugen, Inc., a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that Health Canada provided a “No Objection Letter” to initiate the OCU400 Phase 3 liMeliGhT clinical trial in Canada. OCU400 is a modifier gene therapy product candidate being developed for retinitis pigmentosa (RP). These focus on developing novel therapeutics, boosting market growth in the region.
In addition, there are increasing research activities and clinical trials in the region for developing more advanced therapeutics for the better management of retinitis pigmentosa, which also helps to drive the market in the region. As the research activities and clinical trials increase, therapeutics are developed more precisely by reducing the complications associated with the different types of therapies, resulting in better patient outcomes.
Key Developments in the Retinitis Pigmentosa Treatment Market
August 2026: Ocugen completed Process Performance Qualification batches for OCU400, supporting manufacturing readiness for its planned BLA and potential commercialization. The Phase 3 liMeliGhT program remains on track for topline results in Q1 2027.
- July 2026: MeiraGTx secured up to $400 million in strategic financing to support development and commercialization of botaretigene sparoparvovec (bota-vec), an investigational gene therapy for X-linked retinitis pigmentosa (XLRP).
- April 2026: MeiraGTx acquired global rights to botaretigene sparoparvovec from Johnson & Johnson and announced plans to immediately pursue regulatory filings across major global markets for XLRP.
- March 2026: Ocugen completed enrollment of 140 patients in the Phase 3 liMeliGhT trial of OCU400, a gene-agnostic modifier gene therapy designed to address multiple RP mutations through a single therapeutic approach.
- January 2026: Ocugen entered 2026 targeting a rolling BLA submission for OCU400, with the company continuing development of its gene-agnostic platform intended to provide a one-time treatment approach for broad RP populations.
Retinitis Pigmentosa Treatment Market Top Companies
Top companies in the retinitis pigmentosa treatment market include Spark Therapeutics, Inc., jCyte, Inc., Coave Therapeutics, Kiora Pharmaceuticals, Inc., Aldeyra Therapeutics, Inc., Beacon Therapeutics, ViGeneron GmbH, Nanoscope Therapeutics Inc., SparingVision, Inc., and Endogena Therapeutics Inc., among others.
Key Takeaways
- The increasing development of gene-based and mutation-targeted therapies is emerging as a key industry trend in the retinitis pigmentosa treatment market, with developers focusing on approaches designed to address the underlying genetic causes of retinal degeneration rather than relying solely on supportive vision-management strategies.
- North America maintains a strong position in the retinitis pigmentosa treatment landscape, supported by advanced ophthalmic research infrastructure, established biotechnology capabilities, access to specialized retinal care, and continued clinical development of innovative therapies for inherited retinal diseases.
- Asia-Pacific is emerging as an important growth region as genetic testing capabilities, ophthalmology infrastructure, rare-disease awareness, and investment in advanced retinal therapies continue to expand across markets including China, Japan, India, South Korea, and Australia.
- The limited availability of approved disease-modifying treatments remains a major factor shaping the market, as Luxturna is specifically indicated for patients with confirmed biallelic RPE65 mutations, leaving most retinitis pigmentosa patients dependent on supportive management or investigational therapies.
- Clinical development of broader gene therapies is creating new opportunities across the treatment landscape. In March 2026, Ocugen announced completion of enrollment in the Phase 3 liMeliGhT trial of OCU400, a modifier gene therapy being investigated for broad retinitis pigmentosa, with topline data expected in the first quarter of 2027.
- The growing diversity of genetic targets is encouraging investment in specialized therapies for inherited retinal diseases, with companies advancing programs directed at individual disease-associated genes as well as broader approaches intended to address multiple genetic causes of retinitis pigmentosa.
- Industry participants are increasingly focusing on clinical differentiation, durability of vision-related outcomes, patient selection through genetic diagnosis, retinal delivery techniques, and regulatory pathways when advancing retinitis pigmentosa therapies, reflecting the complex genetic and clinical characteristics of the disease.
Retinitis Pigmentosa Treatment Market Scope
Metrics | Details | |
CAGR | 7.7% | |
Market Size Available for Years | 2023-2033 | |
Estimation Forecast Period | 2026-2033 | |
Revenue Units | Value (US$ Bn) | |
Segments Covered | Disease Type | Non-Syndromic Retinitis Pigmentosa and Syndromic Retinitis Pigmentosa |
Treatment Type | Gene Therapy, Vision Rehabilitation, Sunglasses, Vitamin A Supplements, Omega-3 Fatty Acids, Surgery, and Others | |
Regions Covered | North America, Europe, Asia-Pacific, South America, and the Middle East & Africa | |
The global Retinitis Pigmentosa Treatment market report delivers a detailed analysis with 54 key tables, more than 45 visually impactful figures, and 157 pages of expert insights, providing a complete view of the market landscape.
Why Choose DataM?
- Therapeutic Innovation: Explores advances in retinitis pigmentosa (RP) treatment, including gene replacement therapies, gene-editing approaches, optogenetic therapies, cell-based therapies, and emerging pharmacological strategies. The analysis distinguishes established treatment approaches from investigational technologies, including the development of gene therapies targeting specific genetic causes of inherited retinal degeneration.
- Treatment Performance & Market Positioning: Evaluates treatment approaches based on clinically relevant parameters such as genetic eligibility, mechanism of action, route of administration, retinal-cell viability requirements, visual-function outcomes, durability, safety considerations, and treatment applicability across different RP subtypes. The assessment also considers how mutation-specific therapies differ from gene-agnostic approaches.
- Real-World Evidence: Highlights the use of low-vision aids, vision rehabilitation, genetic testing, and management of associated ocular complications, while assessing the emerging clinical evidence surrounding advanced therapies. FDA-approved LUXTURNA provides an established example of gene therapy for patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy, while other gene, cell, and optogenetic approaches remain under investigation.
- Market Updates & Industry Changes: Tracks regulatory approvals, orphan-drug designations, clinical-trial progress, gene-therapy development, technological breakthroughs, R&D collaborations, and advances in retinal disease treatment. Current development activity includes approaches targeting specific mutations as well as gene-agnostic optogenetic strategies for advanced retinal degeneration.
- Competitive Strategies: Analyzes how pharmaceutical, biotechnology, gene-therapy, and ophthalmology companies pursue growth through targeted gene therapies, gene editing, optogenetics, cell therapy, clinical development partnerships, orphan-drug strategies, and expansion of treatment platforms across inherited retinal diseases. The competitive landscape also reflects the distinction between mutation-specific therapies and technologies designed to address broader patient populations.
- Pricing & Market Access: Examines market-access considerations associated with advanced RP treatments, including treatment eligibility, genetic diagnosis, specialized retinal centers, administration requirements, clinical infrastructure, regulatory status, reimbursement considerations, and the economic implications of potentially one-time gene therapies. Market access is particularly relevant for rare-disease therapies requiring specialized genetic and ophthalmic evaluation.
- Market Entry & Expansion: Identifies opportunities arising from the substantial unmet need in inherited retinal disease, increasing development of gene and cell therapies, advances in genetic diagnosis, and the expansion of gene-agnostic treatment platforms. It also evaluates potential expansion strategies through mutation-specific therapies, broader retinal-disease platforms, strategic partnerships, clinical-trial networks, and access to specialized ophthalmic treatment centers.
Target Audience
- Pharmaceutical & Biotechnology Companies
- Gene Therapy Developers & Manufacturers
- Inherited Retinal Disease Drug Developers
- Ophthalmology & Retinal Disease Treatment Companies
- Cell Therapy & Regenerative Medicine Companies
- Clinical Research Organizations (CROs)
- Specialized Ophthalmic & Retinal Care Centers
